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The IGF system is currently recognized as a risk factor for the
major epithelial cancers (Burroughs et al, 1999). Circulating levels
of IGF-I derive primarily from hepatic synthesis and whether they
affect IGF-I tissue bioactivity is not well known (Pollak, 2000).
However, the positive association between high plasma IGF-I
levels and cancer risk suggest that not only does it act as a tissue
growth factor, but circulating IGF-I also exerts an endocrine role
(Pollak, 1998). This evidence lends further credence to the hypoth-
esis that strategies designed to lower circulating levels of IGF-I
may be relevant in interfering with cancer initiation and/or
progression. 
In particular, a large amount of evidence is accumulating
concerning the role played by IGF-I and its major binding protein
IGFBP-3 in predicting pre-menopausal breast cancer risk
(Hankinson et al, 1998) and prognosis (Vadgama et al, 1999). Both
hormonal and non-hormonal agents, namely tamoxifen and the
synthetic retinoid fenretinide, have been shown to lower circu-
lating IGF-I (Pollak, 1998; Torrisi et al, 1993) and to decrease
breast cancer incidence (Fisher et al, 1998; Veronesi et al, 1999),
although the relationship between these two effects is currently
under investigation. 
The benzothiophene selective oestrogen receptor modulator
(SERM) raloxifene was approved by the FDA for use in the
prevention and treatment of osteoporosis in postmenopausal
women. Within a randomized multicentric trial carried out in post-
menopausal osteoporotic women using risk of vertebral fractures as
the main endpoint (MORE trial), a 76% reduction in invasive breast
cancer was observed after treatment with raloxifene 60 mg or 120
mg for 40 months (Cummings et al, 1999). Although experience
with raloxifene in advanced disease is limited (Buzdar et al, 1988;
Gradishar et al, 2000), it has been shown that raloxifene is able to
decrease a marker of breast tumour proliferation (Ki67) when
administered prior to surgery in women with postmenopausal
breast cancer (Dowsett et al, 2001). In the present study, we inves-
tigated the effects of short-term administration of raloxifene in two
different doses, and the occurrence of a dose–response relationship
on IGF-I, IGFBP-3 and the IGF-I/IGFBP-3 ratio levels in post-
menopausal women with primary breast cancer. 
MATERIALS AND METHODS 
Study design and subjects 
A randomized, phase II placebo-controlled multicentric trial was
designed to assess the activity of two different doses of raloxifene
(60 mg/d vs 600 mg/d) for 14 d before definitive surgery in post-
menopausal breast cancer patients, as described previously
(Dowsett et al, 2001). Women aged 50–80, with newly diagnosed
stage I–II breast cancer were eligible. Patients gave their written
informed consent. A total of 167 women were enrolled in 10 centres
in the UK and at the European Institute of Oncology in Italy. The
study was approved by the Ethical Review Board at each centre. 
The present study on the IGF system was conducted in a
subgroup of 37 women admitted to the European Institute of
Oncology of Milan who were enrolled in this multicentric trial. 
Blood samples were obtained at randomization and after a 
14-day treatment course. Plasma and serum were separated by
centrifugation and aliquots were stored at –20˚C until assayed. All
assays were performed by one of the authors of this study (HJ),
who was blinded as to treatment allocation. 
Assay methods 
Plasma concentrations of IGF-I were determined by enzyme-
linked immunosorbent assay (ELISA) kits purchased from
Diagnostic Systems Laboratories, Inc. (Webster, TX, USA). 
The sensitivity of the assay was 0.03 ng/ml; intra- and interassay
coefficients of variation were 4.9% and 7.9%, respectively. In
order to avoid interference by IGF-binding proteins, the assay
Effect of raloxifene on IGF-I and IGFBP-3 in
postmenopausal women with breast cancer 
R Torrisi1, L Baglietto3, H Johansson1,2, G Veronesi4, B Bonanni1, A Guerrieri-Gonzaga1, B Ballardini4 and A Decensi1
1Division of Chemoprevention; 2Laboratory Medicine Unit; 3Division of Epidemiology and Biostatistics and 4Senology, European Institute of Oncology, via
Ripamonti 435, 20141 Milan, Italy 
Summary The effect on the IGF system of 60 mg and 600 mg daily of raloxifene administered for 2 weeks prior to surgery was investigated
in 37 postmenopausal women with breast cancer. Raloxifene significantly decreased insulin-like growth factor (IGF-I) as compared to placebo
(P < 0.05) with no dose–response relationship. No significant change was observed in IGFBP-3, while the IGF-I/IGFBP-3 molar ratio was
decreased by treatment, with a statistically significant effect only for the higher dose. Given that high plasma levels of IGF-I have been
suggested as a risk factor for breast cancer, these findings provide further support for the potential activity of raloxifene in breast cancer
prevention. © 2001 Cancer Research Campaign http://www.bjcancer.com
Keywords: breast cancer prevention; SERMs; IGF system 
1838
Received 21 February 2001 
Revised 29 August 2001 
Accepted 3 October 2001 
Correspondence to: A Decensi 
British Journal of Cancer (2001) 85(12), 1838–1841
© 2001 Cancer Research Campaign
doi: 10.1054/ bjoc.2001.2191, available online at http://www.idealibrary.com on  http://www.bjcancer.comRaloxifene and the IGF system 1839
British Journal of Cancer (2001) 85(12), 1838–1841 © 2001 Cancer Research Campaign
method was preceded by an acid/ethanol extraction procedure, as
previously described (Daughaday et al, 1980). 
Serum IGFBP-3 concentrations were measured by ELISA kits
purchased from Diagnostic Systems Laboratories, Inc. (Webster,
TX, USA). The sensitivity of the assay was 0.04 ng/ml; intra- and
interassay coefficients of variation were 3.3% and 5.7%, respec-
tively. 
Statistical methods 
The concentrations of IGF-I, IGFBP-3 and the IGF-I/IGFBP-3
ratio measured before and after the treatment were analysed as
repeated measures data. The percentage change, calculated as the
ratio between the difference of post- and pre-treatment values and
pre-treatment values, was assessed for each response variable.
Since age and body mass index (BMI) may affect IGF-I levels,
they were included in the model as categorized variables. In order
to take into account the correlation between repeated measures of
the response variables within the same subject, data were analyzed
using a mixed model with the intercept fitted as a random effect at
subject level (Goldstein, 1995). Analysis was performed using
log-transformed data. Data were analysed using the SPLUS 2000
(MathSoft Inc., Seattle, WA, USA). Statistical significance was
defined as two-tailed P < 0.05. 
RESULTS 
The main patient characteristics are described in Table 1. Age and
BMI, which both may affect the IGF system, were comparable in
the groups. At baseline, no significant difference in IGF-I, IGFBP-
3 or their molar ratio was observed between the three groups. As
for the expression of oestrogen receptors, there was a lower
proportion of subjects with negative receptors in the group of
women treated with raloxifene as compared with placebo. Results
of the IGF changes after treatment are summarized in Table 2. 
After 2 weeks of treatment, IGF-I declined significantly in the
raloxifene (RAL) 60 and the RAL 600 groups as compared with
placebo (P < 0.05) (Figure 1). The magnitude of IGF-I decline was
not significantly different between the two doses (Figure 1). Com-
parable results were obtained when the analysis was performed
while adjusting for IGFBP-3 (data not shown). 
IGFBP-3 was significantly decreased by treatment as compared
to baseline in the RAL 60 group with a mean percentage change of
–10% ± 3. However, when a comparison among groups was
performed, this decrease was not significantly different from the
5% reduction observed in the placebo group and from the absence
of change observed in the RAL 600 group (Figure 1). No signifi-
cant difference among groups was also observed when the analysis
was performed while adjusting for IGF-I (data not shown). 
As a consequence of these results, the IGF-I/IGFBP-3 molar
ratio was significantly decreased by treatment and a trend towards
a dose–response effect was evident, with a mean percentage
change of –13% ± 3 and –23% ± 3 in the RAL 60 and RAL 600
groups, respectively (Figure 1). 
Similar results were observed when the effect of raloxifene on
the IGF system was investigated separately according to the
hormone receptor status (data not shown). Although the number of
ER-negative tumours was too small to draw any conclusions on
the ability of the ER status to affect raloxifene activity, this
analysis was aimed at confirming the consistency of the main
effect in subgroups. 
Age and BMI did not modify the effect of treatment on IGFs
(data not shown). 
DISCUSSION 
The use of intermediate endpoint biomarkers for a rapid evaluation
of the activity of preventive drugs is strongly encouraged in
chemoprevention trials, in the attempt to reduce the number of
subjects and the length of observation required (Kelloff et al,
1994). Recent epidemiological studies show circulating IGF-I to
be a candidate endpoint biomarker of carcinogenesis in several
epithelial tissues (Burroughs et al, 1999). While the efficacy of
raloxifene use in breast cancer prevention is currently undergoing
evaluation in comparison with tamoxifen in a randomized trial
(STAR trial) in the USA, the short-term effects of the drug on
proliferation and circulating IGF-I levels have been investigated in
an attempt to further characterize a biological mechanism for a
possible breast cancer prevention effect. 
The results of the present study show that raloxifene decreases
circulating IGF-I and the IGF-I/IGFBP-3 molar ratio in women
with postmenopausal breast cancer. The magnitude of this
decrease is comparable to that observed with other SERMs such as
tamoxifen (Lonning et al, 1992) and droloxifene (Helle et al,
1996), although raloxifene was administered for a shorter period
(14 days vs 1–3 months for other SERMs). Just as with tamoxifen
(Decensi et al, 1998), but in contrast with droloxifene (Helle et al,
1996), no dose–response effect was observed on IGF-I decline. A
trend towards a greater effect on the IGF-I/IGFBP-3 ratio was
evident for the higher dose, probably due to the IGFBP-3 decline
in the lower dose group. The latter finding should be regarded with
some caution, since we cannot rule out the possibility that it
occurred by chance. 
The clinical implication of the present findings is still unre-
solved. Circulating IGF-I has not been found to be related to breast
cancer risk in postmenopausal women in either of the two large
Table 1 Patient characteristics at the baseline 
Placebo  RAL 60  RAL 600  
n = 11 n = 13 n = 13
Age (yrs) 63 ± 7 60 ± 7 62 ± 6 
BMI (kg/m2) 25.2 ± 5.6 26.6 ± 5.1 26.2 ± 4.7 
ER status (+/–/uk) 6/5/0 9/2/2 9/2/2 
IGF-I (nM/L) 24.2 ± 10.9 20.8 ± 6.1 22.7 ± 6.1 
IGFBP3 (nM/L) 171.9 ± 28.9 167.7 ± 19.3 168.1 ± 31.3 
IGF ratio 0.14 ± 0.04 0.12 ± 0.03 0.13 ± 0.02 
RAL 60 = raloxifene 60 mg/day; RAL 600 = raloxifene 600 mg/day; BMI = body
mass index; ER = estrogen receptor; +/–/uk = positive/negative/unknown; IGF
ratio = IGF-I/IGFBP-3 molar ratio. Data are expressed as mean ± SD value. 
Table 2 Percentage change from baseline after 14 days of treatment 
Placebo  RAL 60  RAL 600 
(n = 11) (n = 13) (n = 13)
IGF-I – 8±5 – 21 ± 4a – 23 ± 4a
IGFBP-3 – 5±3 – 10 ± 3 – 1±3  
IGF ratio – 3±5 – 13 ± 4 – 23 ± 3b,c
RAL 60 = raloxifene 60 mg/day; RAL 600 = raloxifene 600 mg/die; IGF ratio =
IGF-I/IGFBP-3 molar ratio. aP < 0.05 vs placebo; bP < 0.001 vs placebo; 
cP < 0.05 vs RAL 60. Data are expressed as mean ( ± SE) value. 1840 R Torrisi et al 
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prospective studies (Hankinson et al, 1998; Toniolo et al, 2000);
therefore it is unclear whether the results of this study may be
extrapolated to pre-menopausal, at-risk women. In addition, the
means whereby circulating IGF-I may affect breast carcinogenesis
is still unclear. Recent findings suggest that the autocrine/paracrine
activity of the growth factor is independent of its serum levels
(Yakar et al, 1999). On the other hand, exogenous administration
of IGF-I positively affects breast cell proliferation (Ng et al, 1997),
supporting the hypothesis that circulating growth factor exerts a
direct role on breast cell growth. 
Given the putative role of IGF-I in breast carcinogenesis, the
reduction of circulating IGF-I may be involved in the preventive
effect of raloxifene. Debate is still open as to whether SERMs are
true preventative agents or whether they treat the occult disease.
Convincing arguments have been proposed in support of either
mechanism, which may concur in reducing the clinical expression
of the tumour (Radmacher and Simon, 2000). Consistent with this
hypothesis, the early reduction of breast cancer incidence in the
MORE trial may represent the suppression of subclinical cancer
(Cummings et al, 1999), while the increasing separation of the
curves of breast cancer occurrence up to 44 months (Cauley et al,
2001), suggests that the drug also exerts an early inhibitory effect
on carcinogenesis, thus preventing the occurrence of a fully trans-
formed phenotype (Brown and Lippman, 2000). Whatever the
mechanism of raloxifene activity, a decrease of circulating IGF-I
levels is desirable. In fact, although IGF-I has not been shown to
predict postmenopausal breast cancer risk, the growth factor may
intervene in different stages of breast carcinogenesis, since it induces
proliferation, inhibits apoptosis and stimulates angiogenesis, thus
favouring not only the appearance but also the maintainance of a
transformed phenotype (Baserga, 1995; Yu and Rohan, 2000).
Indeed, the evidence that the preventive activity of SERMs is
restricted to ER-positive tumours and the reciprocal interaction
between the oestrogen and the IGF-I signalling pathways suggest
that the decrease of IGF-I may have some relevance, if any,
in preventing the development of ER-positive breast cancer.
However, the occurrence of a ER-negative phenotype is still
unclear and the timing of ER changes in breast carcinogenesis
appears to be very complex (Brown and Lippman, 2000). 
In a similar manner to the results of the MORE trial, no
dose–response effect was observed on IGF-I decline, suggesting
that saturation of the oestrogen receptor occurs with the lower
dose. The decrease in both IGF-I and proliferation, as assessed by
Ki67 (Dowsett et al, 2001) may be possible mechanisms for the
breast cancer preventive effect of raloxifene (Dowsett et al, 2001). 
While the decline of circulating IGF-I may be desirable in breast
cancer prevention, the implication of this finding for other situa-
tions is less clear. In addition to cancer, the IGF system is largely
involved in bone formation and turnover. The circulating IGF
system predicts the levels of markers of bone formation such as
osteocalcin, although its relationship with bone mineral density
(BMD) is less definite (Boonen et al, 1999; Collins et al, 1998).
While lower levels of circulating IGF-I have been associated with
an increased risk of vertebral fractures in postmenopausal women
(Garnero et al, 1999), raloxifene administration for 3 years was
associated with a 50% reduction in the risk of incident vertebral
fractures in postmenopausal women despite the decrease in serum
concentrations of osteocalcin (Ettinger et al, 1999) and in circulating
IGF-I levels observed in the present study. Since mechanisms other
than the increase of BMD may contribute to the anti-osteoporotic
activity of raloxifene (Cummings, 2000) the decline of plasma
IGF-I may not be a determining factor in this effect of the drug. 
Figure 1 Percentage (%) change ± 95% CI of IGF-I, IGFBP-3 and the IGF-I/IGFBP-3 ratio after 2 weeks of treatment. * P < 0.05 vs placebo; ** P < 0.001 vs
placebo; *** P < 0.05 vs RAL 60
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In conclusion, raloxifene decreases circulating IGF-I and the
IGF-I/IGFBP-3 ratio after short-term administration in post-
menopausal women. The implication of these findings for the
possible breast cancer preventive activity of raloxifene merits
further investigation. 
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